Acute Inflammation and Resolution: Definitions and Key Mechanisms {#sec1}
=================================================================

Acute inflammation is a protective process arising in vascularized tissues upon damages, altered homeostasis, and infections. Its macroscopic hallmarks, or "cardinal signs," identified by Celsus in the first century BC encompass *rubor* (redness), *tumor* (swelling), *calor* (heat), and *dolor* (pain) ([@ref123]), which arise from responses of tissue resident and blood-borne cells that are regulated by chemical signals, such as prostaglandins (PG), thromboxane (TX), leukotrienes (LT), cytokines, and chemokines. Increase in permeability of microvessels determines plasma fluid leakage and accumulation in tissues, leading to edema ([Figure 1](#fig1){ref-type="fig"}). This is followed by polymorphonuclear neutrophil (PMN) recruitment, adhesion to vascular endothelial cells, diapedesis (or transmigration), and accumulation or swarming. Their primary function is to eliminate bacteria or other damaging substances mainly *via* phagocytosis, i.e., the engulfment of foreign bodies inside intracellular vacuoles (phagosomes) and their disposition ([@ref84]). PMNs also release their granule contents, DNA, and chromatin proteins to form extracellular fibers that immobilize and kill bacteria. Neutrophil extracellular traps (NETs) represent a potent, innate mechanism by which PMNs prevent microbe spreading following infection ([@ref21]). PMNs undergo rapid apoptosis and are actively removed by macrophages (MФs) differentiated from monocytes entering as a second wave in inflamed tissues in a process termed "efferocytosis" ([@ref28]). Studies also indicate that PMNs can exit the inflammatory loci *via* lymphatic vessels or lining adipose tissue (lipopassage) ([@ref188]). MФs are also capable of clearing bacteria, pathogenic substances, and debris. Ideally, their action occurs in a non-phlogistic way and allows the resolution of inflammation ([@ref189]). Cardinal signs of resolution are: (1) limitation/cessation of PMN infiltration, (2) sequestration and counter-regulation of pro-inflammatory chemical mediators, (3) apoptosis of PMN and removal (e.g., by efferocytosis), (4) clearance of pathogens, inflammatory stimuli, and cell debris, and (5) tissue repair.

![The acute inflammatory response and its ideal outcome: essential steps, mechanisms, and definitions. Injury, infections, or dysregulated homeostasis ignites the acute inflammatory response that is normally a host protective mechanism. The first event in acute inflammation is edema formation, followed by infiltration of PMN, and then monocyte and macrophages that clear PMN leading to resolution, which is essential for ensuring host protection and sparing from tissue damage.](fphar-10-00252-g001){#fig1}

MФs are master cells in resolution since they have specialized functions, also mirrored by specific cellular and molecular phenotypes ([@ref201]), that permit the clearance of pathogens, infiltrated leukocytes, or inflammatory debris and regulate the tissue remodeling or repair ([@ref83]). It is now evident that failure to resolve inflammation in a proper and timely manner preludes to pathology since the persistence of the phlogistic process can lead to tissue damage or systemic disease ([@ref139]). Therefore, what makes inflammation an "unwanted" process it is not how often or how extensive it starts, but how quickly and effectively it resolves.

Non-Resolving Airway Inflammation in Cystic Fibrosis {#sec2}
====================================================

Unresolved acute inflammation and chronic infection, mainly due to *P. aeruginosa*, are key mechanisms responsible for progressive airways destruction in cystic fibrosis (CF), the most common hereditary human disease ([@ref56]; [@ref27]). In CF patients, airway inflammation starts early in life, persists even in the absence of detectable microbial colonization, is exaggerated in magnitude compared to the burden of infection, and does not resolve ([Table 1](#tab1){ref-type="table"}). Despite ground-breaking advances in CF therapies obtained with the discovery of drugs that correct or potentiate the defective CF transmembrane conductance regulator (CFTR) protein, the unrelenting inflammatory response in the airways and persistent, recurrent infections remain the principal cause of progressive lung disease in patients, contributing to the high morbidity and early mortality of CF, with \~800 life losses/year ([@ref44]; [@ref223]). Remarkably, current anti-inflammatories, like ibuprofen, that block the activation phase of inflammation by inhibiting cyclooxygenase (COX)-derived prostanoids have provided little clinical benefits to patients ([@ref115]), suggesting that multiple factors contribute to airway inflammation in CF. Hence, different strategies must be explored, considering that the risk/benefit ratio for anti-inflammatories in CF is particularly narrow since inflammation is required for restraining bacterial spread.

###### 

Hallmarks of airway inflammation in patients with CF.

  Hallmarks of airway inflammation in CF
  -------------------------------------------------------------
  1\. Begins early in life
  2\. Is disproportionate to the degree of infection
  3\. Starts and/or persists even in the absence of infection
  4\. Never resolves

The unrelenting, non-resolving lung inflammation in CF patients is participated by a number of cells, stimuli, and cellular pathways ([Figure 2](#fig2){ref-type="fig"}). Although lung of neonates with CF is structurally normal, bronchiolar mucus plugging, inflammation, and hypertrophy of submucosal gland ducts are evident as early as few months of age even without detectable infections ([@ref15]; [@ref202]). Once patients with CF are challenged by bacterial or viral infection, airway inflammation is disproportionate to the degree of infection, with a high PMN infiltration and large release of pro-inflammatory molecules, such as tumor necrosis factor (TNF)-α, interleukin (IL)-8, 6, 1β ([@ref9]; [@ref18]; [@ref145]; [@ref138]; [@ref209]; [@ref137]), prostaglandins, and LTB~4~ ([@ref108]). More importantly, lung inflammation in CF appears incapable of removing pathogens effectively and never resolves ([@ref177]).

![Airway inflammation in CF. A schematic view of the inflammatory response and a few of the secondary pathologic findings in CF airways. Microbial infection (by *P. aeruginosa, S. aureus, Non-tuberculosis Mycobacterium,* and other pathogens) incites a vigorous, disproportionate inflammatory response. PMNs infiltrate the airway and release proteases and oxidants that damage the airway and chemoattractants that stimulate further neutrophil influx. Although neutrophils and epithelial cells have been most intensely investigated, alterations in endothelial cells (EC), macrophages (MΦ), platelets (PLT), and T lymphocytes also play a pathophysiological role in CF airway non-resolving inflammation. See within text for further details. Not all mediators and cell types implicated in CF are shown.](fphar-10-00252-g002){#fig2}

PMNs are the predominant leukocytes contributing to airway inflammation in CF. Once recruited at CF airway tissues, they play an important defense function by phagocytosing microorganisms, secreting antimicrobial peptides, and entrapping microbes in neutrophil extracellular traps (NETs), DNA meshes formed of released DNA and proteins. However, in CF, excessive and uncontrolled neutrophil infiltration and activity have pathologic consequences, with the release of proteolytic enzymes that can degrade extracellular membrane and tissues, oxidant species that can cause structural damages to the airways and further aliment inflammation, and NETs that increase mucus viscosity ([@ref141]).

Macrophages also contribute to the non-resolving inflammation in CF airways ([@ref22]). Data indicate that MΦs of CF patients have a hyper-responsive phenotype, producing a high amount of inflammatory cytokines when exposed to bacterial stimuli ([@ref23], [@ref24]). This abnormal response may arise to basic defects in CFTR or to the persistence in bacterial colonization. CF MΦs also seem to have a defective ability to clear bacteria (possibly secondary to impaired acidification of phagosome due to CFTR dysfunction) ([@ref61]; [@ref59]; [@ref57]), although this is not completely understood ([@ref91]).

In addition to the well-known role in regulating vascular tone, blood fluidity, and hemostasis, platelets (PLTs) have important roles in innate immunity and inflammation. PLT can release nitric oxide (NO) and prostanoids that control leukocyte interactions with endothelial cells (EC), respond to pathogens, and interact with blood leukocytes dictating their fate and functions ([@ref182]). Clinical-based and *ex vivo* evidence of increased PLT activation in CF has been documented, suggesting that these cells can contribute to inflammation in these patients ([@ref37]; [@ref149]; [@ref121]) Moreover, PLTs are important effector of resolution, since they carry enzymes and substrates required for the biosynthesis of pro-resolving mediators. PLT interactions with PMN, a key process occurring during inflammation, lead to the formation of lipoxins (LX) A~4~ ([@ref181]; [@ref178]), the first identified specialized pro-resolving lipid mediator (SPM) that stops inflammation and promotes return to homeostasis ([@ref179]). A study from Mattoscio and coworkers demonstrated that defective CFTR function expressed at PLT surfaces decreases LXA~4~ formation by inhibiting PLT LX synthase activity ([@ref129]). In the same study, the authors also provided compelling evidence that PLTs isolated from volunteers with CF produce significantly less NO and have an increase pro-survival activity in PMN, thus prolonging the duration of inflammation ([@ref129]). Critical roles of PLT in inflammation and immunity have been recently confirmed in a preclinical model of *P. aeruginosa* lung infection ([@ref5]), further underlining the involvement of these cells in CF lung inflammation.

Epithelial cells form the lining of airway tissues and are the first encounter of microbes and other toxins that activate the acute inflammatory reactions. CFTR is abundantly present on the apical side of airway epithelial cells (AECs), and the absence of a functional protein causes incomplete cAMP-dependent Cl^−^ and HCO~3~ ^−^ secretion in airway. Therefore, mucus becomes dehydrated ([@ref157]), mucins (main protein components of secretions) are tethered at apical AEC surfaces ([@ref109]; [@ref124]; [@ref122]), and extracellular pH is decreased ([@ref130]), thus impairing host antimicrobial defenses (see [@ref27]; [@ref177] for a more complete review on this topic). Increased release inflammatory cytokines and chemokines through NF-κB and intracellular stress signals (e.g., Ca^2+^) have been largely documented in AEC isolated from CF patients ([@ref216]; [@ref157]; [@ref101]) and can contribute to the non-resolving feature of inflammation in CF ([@ref177]).

Vascular endothelial cells (ECs) have pivotal roles in regulating inflammation, controlling the leakage of plasma proteins as well as leukocyte infiltration by releasing soluble mediators such as NO, IL-8, PG, and TX ([@ref81]). CFTR expression in EC and the involvement of CFTR in response to hypoxia have been documented ([@ref212]; [@ref206]). In addition, clinical signs of EC dysfunctions in individuals with CF have been documented ([@ref212]; [@ref180]; [@ref166]). Recently, Totani and coworkers have shown that CFTR controls homeostatic functions of EC. In particular, CFTR blockade increased EC permeability and loss of membrane integrity under flow. Also, CFTR blockade suppressed NO generation and enhanced IL-8 release, possibly contributing to the sustained PMN recruitment in CF. Remarkably, in the same study, the authors showed that a combinatorial treatment with phosphodiesterase inhibitors and β2 adrenergic receptor agonists corrected CFTR-dependent EC abnormalities providing novel cellular targets for treating inflammation in CF ([@ref211]).

Many dysregulated T cell subsets and related cytokines have been identified in CF lung, including Th17 that can promote PMN influx by producing IL-8 and IL-17, suggesting that T lymphocytes have important roles in lung inflammation in CF ([@ref113]).

The introduction of CFTR correctors and potentiators allowed gaining of CFTR function in individuals carrying some mutations ([@ref142]; [@ref63]). However, whether a better CFTR function translates into improvements in lung inflammation and infections is unclear. In a sub-study of the GOAL trial, Rowe and colleagues found a trend downward in abundance of CF pathogens such as *Pseudomonas* and *Staphylococcus* in the airways of study participants treated with ivacaftor, but no changes in inflammatory markers, including IL-6, -8, -1β, and free elastase in sputum ([@ref183]; [@ref97]). In a subsequent study, Hisert and colleagues found that *P. aeruginosa* abundance in subjects treated with ivacaftor declined during the first year of treatment but started to increase afterwards. Concentrations of sputum inflammatory markers were also reduced, even if still present in huge quantities at the end of the study ([@ref99]). It is conceivable that, as infection rebounds, inflammation will eventually follow.

Given the myriad of cellular, soluble, and intracellular players that can contribute to chronic inflammation in CF, an ideal anti-inflammatory drug for these patients should target many component of this excessive inflammatory response and stimulate resolution.

Resolution of Inflammation is an Active Process {#sec3}
===============================================

Pioneer work by Dr. Serhan and coworkers (see [@ref195] for a recent review) and from many others worldwide ([@ref186],[@ref187]; [@ref158]; [@ref159]; [@ref189]) has demonstrated that resolution is an *active process* regulated by specific mediators ([@ref160]) and changed the traditional view of resolution. Endogenous SPMs produced from essential polyunsaturated fatty acids (PUFAs) stop excessive PMN infiltration, counter pro-inflammatory signals, and enhance the active clearance of pathogens and death cells by MΦ. Collectively, SPMs accelerate the restitutio ad integrum; thus, they are often referred as "immunoresolvents" ([@ref48],[@ref49]) or "agonists of resolution" ([@ref188]; [@ref30]). In addition to LX, the SPM genus includes E, D, and T series resolvins (Rv), protectins (PD), and maresins (MaR) that are biosynthesized through transcellular routes involving both resident and blood cells by lipoxygenase (LO) enzymatic activity from arachidonic acid (AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), or docosahexaenoic acid (DHA) available in inflammatory exudates ([Figure 3](#fig3){ref-type="fig"}; [@ref106]).

![Biosynthesis and structures of SPM. The biosynthetic pathways leading to lipoxins **(A)**, E-series resolvins **(B)**, SPM derived from DPA **(C)**, D-series resolvins, protectins, and maresins **(D)** are illustrated. Structures and stereochemistries of some members of each SPM family are shown (see text for further details). AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LO, lipoxygenase; COX-2, cyclooxygenase 2. MCTRs, maresin conjugate in tissue regeneration; RCTRs, resolvin conjugate in tissue regeneration; PCTRs, protectin conjugate in tissue regeneration. GST/LTC4S, glutathione-S-transferase/leukotriene C~4~ synthase.](fphar-10-00252-g003){#fig3}

In human system, SPM can be found in biological specimens at pico- to nanogram levels, which are commensurate to their range of activity. SPMs are identifiable in blood ([@ref167]; [@ref800]; [@ref42]; [@ref13]; [@ref47]), breast milk ([@ref217]), breath condensate ([@ref801]), sputum ([@ref802]), urine ([@ref76]; [@ref185]), and tears ([@ref70]). Levels of SPM can vary in response to inflammatory stimuli ([@ref65]; [@ref77]), vascular damage ([@ref20]; [@ref163]), or physical exercise ([@ref76]; [@ref127]). SPMs are also enriched in inflammatory exudates such as synovial fluids from volunteers with rheumatoid arthritis ([@ref147]), skin blisters ([@ref134]; [@ref135], [@ref136]), and bronchoalveolar lavage fluids (BALs) from patients with airway diseases ([@ref116]; [@ref105]; [@ref165]; [@ref172]). Of interest, accruing evidence indicates that SPM levels are often diminished in patients with a more severe disease, are unbalanced compared to pro-inflammatory eicosanoids, and inversely correlate with the clinical status. Several RvDs and Es, PD1, and Mar-1 are reduced in adipose tissue samples from obese subjects ([@ref500]), and RvD1 is significantly lower in vulnerable areas of human atherosclerotic plaques ([@ref73]). LXA~4~ and LXA~4~ to LTB~4~ ratio are decreased in BAL from patients with CF ([@ref105]; [@ref172]). RvD1 levels are further reduced in CF patients with a worse pulmonary function ([@ref802]). Collectively, these studies suggest that reduced levels of SPM may contribute to the progression and worsening of human diseases.

Since resolution is an active process directed by selected mediators, the exploitation of these endogenous controllers of inflammation as therapeutics opened novel opportunities in pharmacology for the treatment of human diseases ([@ref80]; [@ref208]). For example, annexin (Anx) A1, an endogenous protein abundant in PMN granules, and melanocortins dampen inflammation and protect from tissue damage ([@ref95]; [@ref132]; [@ref46],[@ref50]). Similarly, synthetic LX stable analogs showed anti-inflammatory and organ protective activities ([@ref12]; [@ref88]; [@ref204]). Norling and coworkers proved the efficacy of D-series resolvins in ameliorating arthritis ([@ref147]) and joint inflammation ([@ref147]). AnxA1-enriched microvesicles derived from human PMN also convey anti-inflammatory, pro-resolution, and organ protective actions in experimental mandibular joint disease ([@ref148]), arthritis ([@ref94]), and atherosclerosis ([@ref119]). Recently, SPM proved to reduce inflammation in human volunteers undergoing UV-killed *E. coli* skin inflammation ([@ref136]) Hence, the exploration of pharmacological properties of SPM and other chemical mediators of endogenous resolution is of considerable interest ([@ref160]).

In order to define resolution in an unbiased, quantitative manner, Bannenberg et al. defined mathematical "resolution indices" by determining the cellular changes in exudates during an experimental, acute inflammatory reaction (namely local peritonitis in mice induced by injection of zymosan A particles from *S. cerevisiae*, a Toll-like receptor activator) with a fixed "time zero." Resolution indices encompass: *T*~max~, i.e., time point of maximum PMN infiltration (Ψ~max~); *T*~50~, time necessary to achieve 50% reduction in PMN number (Ψ~50~) from Ψ~max~; resolution interval (*R*~i~ = *T*~50~ -- *T*~max~), time interval between *T*~max~ and *T*~50~ ([@ref11]). Resolution indices have been largely used and employed in several preclinical models of inflammatory diseases for testing properties of endogenous chemical mediators or pharmacological agents ([@ref188]; [@ref93]; [@ref140]).

Biosynthesis of SPM {#sec4}
===================

AA Metabolome {#sec5}
-------------

### Lipoxins and Aspirin-Triggered Lipoxins (ATL) {#sec6}

LXs ("lipoxygenase interaction products") such as LXA~4~ and B~4~ are resulting from the enzymatic conversion of AA during cell-cell interactions ([@ref193]; [@ref184]). AA oxygenation by 15-LO and 5-LO, followed by enzymatic hydrolysis of hydro(peroxy)-containing intermediates, results in the formation of LXA~4~ and B~4~ ([@ref65]; [@ref120]; [@ref85]) and reviewed by [@ref169]. In blood, AA is converted into LXA~4~ and B~4~ by the sequential activity of 5-LO (present in leukocytes) and 12-LO (abundant in platelets) ([Figure 3A](#fig3){ref-type="fig"}; [@ref196]; [@ref181]). In vascular cells, acetylation of COX-2 by aspirin renders this enzyme capable of converting AA into 15R-HETE, which then serves as a substrate of leukocyte 5-LO for the biosynthesis of LX containing an OH-group in the *R* configuration at C15 ([Figure 3A](#fig3){ref-type="fig"}; [@ref38]). These "aspirin-triggered" lipoxins (ATLs), also named 15-epi-LX, are produced in human subjects taking aspirin ([@ref29]), and mediate the anti-inflammatory actions of low-dose aspirin in healthy individuals ([@ref134]). Of interest, studies from Birnbaum et al. demonstrated that atorvastatin, in addition to produce a lipid-lowering effect, promotes the generation of 15*R*-LXA~4~ *via S*-nitrosylation of COX-2 in myocardial cells ([@ref17]), whereas Gutierrez et al. showed that pioglitazone, an insulin-sensitizing agent, raises plasma levels of 15-epi-LXA~4~ ([@ref89]). Hence, aspirin, atorvastatin, and pioglitazone can activate the resolution process.

More recently, a study by Lee and coworkers revealed a new mechanism by which 15-epi-LXA~4~ biosynthesis can be activated in the nervous system. In their study, the authors found that sphingosine kinase 1 (a key enzyme that converts sphingosine into the bioactive lipid sphingosine-1-phosphate) acetylates neuronal COX-2 skewing the production of 15-epi-LXA~4~ and other SPM, resulting in an increase in phagocytosis of Aβ-amyloid by microglial cells and improvement of Alzheimer's disease (AD)-like pathology in mice ([@ref117]). Since sphingosine kinase 1 is reduced in human AD neurons ([@ref117]) and several SPMs are diminished in cerebrospinal fluid from patients with AD ([@ref143]; [@ref222]), this study provides a new framework for targeting resolution and SPM to dampen inflammation in AD.

EPA Metabolome {#sec7}
--------------

### E-Series Resolvins {#sec8}

RvE1 (5*S*,12*R*,18*R*-trihydoxy-6*Z*,8*E*,10*E*,14*Z*,16*E*-EPA) ([@ref6]) is produced in endothelial cells by aspirin acetylated COX-2 that converts EPA into 18R-hydro(peroxy)-eicosapentaenoic acid (HEPE), then metabolized by activated leukocytes (e.g., PMN) into RvE1 ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, the 18*R*-HEPE isomer was dominant to its epimer 18*S*-HEPE in plasma from volunteers given EPA, while 18*S*-HEPE was increased by aspirin administration ([@ref501]). 18*S*-HEPE can also be converted to RvE1 and RvE2 by 5-LO and LTA~4~ hydrolase ([@ref152], [@ref151]), and cytochrome P450 mediates the oxygenation of EPA into RvE1 ([@ref190]; [@ref90]). RvE2 (5*S*,18-dihydroxy-EPE) is produced *via* a reduction in 5*S*-hydroperoxy, 18-hydroxy-EPE ([@ref210]; [@ref150]; [@ref152], [@ref151]) in resolving exudates and in human whole blood, while 18*R-*RvE3 (17*R*,18*R*-dihydroxy-5Z,8Z,11Z,13E,15E-EPE) and epimeric 17*R*,18*S*-RvE3 are biosynthesized *via* 12/15-LO in eosinophils ([Figure 3B](#fig3){ref-type="fig"}; [@ref103], [@ref807]).

DPA Metabolome {#sec9}
--------------

EPA is not the only ω-3 fatty acid present in mammalian cells. n-3 docosapentaenoic acid (7Z,10Z,13Z,16Z,19Z-docosapentaenoic acid; n-3 DPA) is an intermediate of EPA biosynthesis from its precursor alpha-linolenic acid ([@ref26]). Using targeted lipid mediator metabololipidomics, Dalli and coworkers identified previously unrecognized SPM derived from DPA that are congenerous to D-series Rv, PD, and MaR. The new n-3 DPA molecules include 7,8,17-trihydroxy-9,11,13,15*E,*19*Z*-DPA (RvD1~n-3\ DPA~), 7,14-dihydroxy-8,10,12,16*Z,*19*Z*-DPA (MaR1~n-3\ DPA~) and related isomers MaR2 and 3~n-3\ DPA~ ([@ref48]), 10R,17S-dihydroxy-7Z,11E,13E,15Z,19Z-DPA (PD1~n-3\ DPA~) ([@ref48]; [@ref8]), and 7S,17S-dihydroxy-8E,10Z,13Z,15E,19Z-DPA (RvD5~n-3\ DPA~) ([@ref82]). Structures of four new bioactive molecules derived from DPA and termed 13-series resolvins (RvT) were recently reported. RvTs carry a 13-carbon position alcohol, and their biosynthesis is dependent upon nitrosylation of COX-2 by atorvastatin ([Figure 3C](#fig3){ref-type="fig"}; [@ref46]).

### D-Series Resolvins {#sec10}

Earlier lipidomic studies of resolving exudates from mice administered DHA and aspirin identified DHA-derived molecules containing an OH-group at C17 ([@ref194]). By using isolated human cells and recombinant enzymes, Serhan and coworkers identified and recapitulated the entire biosynthetic pathways of D-series resolvins. Human endothelial cells exposed to hypoxia express highly amount COX-2 that converts DHA to 13-hydroxy-DHA or 17*R*-HDHA in the presence of aspirin. Both intermediates can be metabolized by human PMN to compounds termed "aspirin triggered" D-series resolvins ([@ref194]). By contrast, in the absence of aspirin, D-series resolvins with the 17*S*-OH group are predominant ([@ref194]; [@ref100]). The complete organic synthesis and the stereochemistry of 17*S*-, 17*R*-RvD1, and RvD2 have been established as follows: 7*S*,8*R*,17*S*-trihydroxy-4*Z*,9*E*,11*E*,13*Z*,15*E*,19*Z*-docosahexaenoic acid (17S-RvD1), 7*S*,8*R*,17*R*-trihydroxy-4*Z*,9*E,*11*E*,13*Z*,15*E*,19*Z*-docosahexaenoic acid (17*R*-RvD1) ([@ref203]), and 7*S,* 16*R*, 17*S*-trihydroxy-4*Z*, 8*E*, 10*Z*, 12*E*, 14*E*, 19*Z*-docosahexaenoic acid (RvD2) ([@ref200]).

Additional members of this family have been identified: RvD3 (4*S*,11*R*,17*S*-trihydroxy-5*Z*,7*E*,9*E*,13*Z*,15*E*,19*Z*-DHA) ([@ref49]), RvD4 (4*S*,5*R*,17*S*-trihydroxy-6*E*,8*E*,10*E*,13*E*,15*Z*,19*Z*-DHA) ([@ref218]), RvD5 (7*S*,17*S*-dihydroxy-4*Z*,8*E*,10*Z*,13*Z*,15*E*,19*Z*-DHA), and RvD6 (4*S*,17*S*-dihydroxy-5*E*,7*Z*,10*Z*,13*Z*,15*E*,19*Z*-DHA).

### (Neuro)Protectins {#sec11}

Although PD1(10*R*,17*S*-dihydroxy-docosa-4*Z*,7*Z*,11*E*,13*E*,15*Z*,19*Z*-hexaenoic acid) ([@ref192]) is the founding member of this family, several isomers that also possess lower bioactivity than PD1 have also been identified: 10*S*,17*S*-diHDHA, 4*S*,17*S-*diHDHA, 7*S*,17*S*-diHDHA, and 22-hydrox-10,17*S*-docosatriene ([@ref194]; [@ref100]), and an aspirin PD1 has been reported ([@ref125]) (10*R*,17*R*-dihydroxy-docosa-4*Z*,7*Z*,11*E*,13*E*,15*Z*,19*Z*-hexaenoic acid) ([Figure 3D](#fig3){ref-type="fig"}).

#### Maresins {#sec12}

Maresins (from *macrophage mediator in resolving inflammation*) are a fourth family of DHA-derived SPM ([@ref102]). The structural elucidation, complete biochemistry assignment, and total organic synthesis of two members of this family have been reported. Mar-1 (7*R,*14*S*-dihydroxy-4*Z*,8*E*,10*E*,12*Z*,16*Z*,19*Z*-DHA) and Mar-2 (13*R*,14*S*-dihydroxy-4*Z*,7*Z*,9*E*,11*Z*,16*Z*,19*Z*-DHA) are produced in tissues by MΦ and in the vasculature during PLT-PMN crosstalk through the action of 12-LO ([@ref197]; [@ref55]; [@ref2]; [@ref58]). *In vivo* and *in vitro* they promote resolution by increasing efferocytosis, skewing MΦ pro-resolutive phenotypes, and inhibiting PMN infiltration. They also hold organ protective and tissue-regenerative actions ([@ref191]). Mar-1 and Mar-2 receptors have not been identified yet.

#### Cysteinyl-Conjugated SPM {#sec13}

Lipidometabolomic profiling of murine exudates, spleens, and human fluids (including blood and breast milk) has revealed new families of SPM covalently bond to cysteine residues, collectively named SPM "conjugated in tissue regeneration" (CTR).

DHA is converted by 12-LO into 13,14-epoxy-Maresin (an intermediate of Mar-1 and Mar-2) that can be directly conjugated at C13 to glutathione by LTC4 Synthase, yielding maresin conjugated in tissue regeneration 1 (MCTR 1;13*R*-glutathionyl, 14*S*-hydroxy-4*Z*,7*Z*,9*E*,11*E*,13*R*,14*S*,16*Z*,19*Z*-DHA), the first identified cysteinyl-SPM. Subsequent cleavage of Glu and Gly residues converts MCTR1 into MCTR2 (13*R*-cysteinylglycyl, 14*S*-hydroxy-4*Z*,7*Z*,9*E*,11*E*,13*R*,14*S*,16*Z*,19*Z*-DHA), and MCRT3 (13*R*-cysteinyl, 14*S*-hydroxy-4*Z*,7*Z*,9*E*,11*E*,13*R*,14*S*,16*Z*,19*Z*-DHA) ([@ref174]). MCTRs accelerate tissue regeneration in planaria, reduce neutrophil infiltration during *E. coli* peritonitis, and stimulate bacterial phagocytosis by MΦ ([@ref45], [@ref52],[@ref54]). They also antagonize LTD~4~ binding to recombinant cysLT receptor 1 and actions in vascular cells (i.e., induction of leakage) and intact hearts (i.e., lowering of heartbeats) ([@ref33]).

Mouse and human leukocytes convert 17H(p) DHA into distinct sets of sulfide-conjugated resolvins and protectins ([@ref50]). Attachment of glutathione at the 7,8-epoxide intermediate of RvD generates resolvin conjugate in tissue regeneration 1 (RCTR1, 8*R*-glutathionyl-7*S*,17*S*-dihydroxy-4*Z*,9*E*,11*E*,13*Z*,15*E*,19*Z*-DHA) that is in turn cleaved into RCTR2 (8*R*-cysteinylglycinyl-7*S*,17*S*-dihydroxy-4*Z*,9*E*,11*E*,13*Z*,15*E*,19*Z*-DHA) by γ-glutamyltranspeptidase and into RCTR3 (8*R*-cysteinyl-7*S*,17*S*-dihydroxy-4*Z*,9*E*,11*E*,13*Z*,15*E*,19*Z*-DHA) *via* peptidases ([@ref176]; [@ref114]). RCTRs stimulate tissue repair *in vivo*, enhance MΦ phagocytosis, and reduce cytokines and PMN recruitment *in vivo* and *in vitro* ([@ref114]).

Binding of glutathione at C16 of 17H(p)DHA produces protectin conjugated in tissue regeneration 1 (PCTR1, 16*R*-glutathionyl-4*Z*,7*Z*,10*Z*,12*E*,14*E*,16*R*,17*S*,19*Z*-DHA) that is converted into PCRT2 (16*R*-cysteinylglycinyl-4*Z*,7*Z*,10*Z*,12*E*,14*E*,16*R*,17*S*,19*Z*-DHA) and PCRT3 (16*R*-cysteinyl-4*Z*,7*Z*,10*Z*,12*E*,14*E*,16*R*,17*S*,19*Z*-DHA) ([@ref175]; [@ref168]). In addition to the name giving tissue regenerative actions, PCTRs possess immune-regulatory actions on innate lymphoid cells during bacterial infection *in vivo* ([@ref47]).

SPM Receptors and Intracellular Signaling {#sec14}
=========================================

SPMs serve principally as ligand agonists to cognate GPCRs to exert cell-specific actions that broadly regulate inflammation and resolution ([Figure 4](#fig4){ref-type="fig"}). Studies from Nigam et al. first demonstrated that LXA~4~ stimulates lipid remodeling and release of AA in PMN in a pertussis toxin-sensitive manner ([@ref144]). Fiore et al. provided the first evidence for stereoselective, specific, and reversible binding of LXA~4~ to human PMN (with a *K*~d~ \~0.5 nM), thus confirming the role of GPCR receptor(s) in conveying bioactions of LXA~4~ ([@ref72]). Subsequently, formyl peptide receptor like-1 was identified as LXA~4~-GPCR in a human neutrophil cell line ([@ref71]). This receptor has been formerly renamed ALX/FPR2 in light of its affinity for LXA~4~ ([@ref221]). ALX/FPR2 is abundantly present in myeloid cells, lymphocytes, dendritic cells, and resident cells ([@ref34]). Orthologs the human ALX/FPR2 gene have been sequenced in rodents ([@ref207]; [@ref35]). In addition to LXA~4~ and ATL, ALX/FPR2 is activated by AnxA1 and its N-terminal peptides bind and activate ALX/FPR2 ([@ref158]), which is the archetype of GPCR conveying both lipid and peptide pro-resolving mediators. Of interest, LXA~4~ also functions as modulator of cannabinoid receptor CB1 ([@ref154]), which may contribute to the anti-nociceptive activities of this SPM ([@ref205]; [@ref1]). In addition, earlier studies demonstrated that 15-*epi*-LXA~4~ also binds at cysteinyl LT receptor 1 (CysLT1) with equal affinity to LTD~4~, providing further evidence for ATL in dampering CysLT signals in the vasculature ([@ref86]). Gain and loss-of-function approaches of ALX/FPR2 in human cells and in mice proved its essential role in mediating LX activities. Indeed, targeted overexpression of human ALX/FPR2 in murine myeloid cells increased the sensitivity to LXA~4~ stable analog, left-shifting the dose-response curve ([@ref60]). On the contrary, ALX/FPR2 nullified mice have an unrelenting inflammatory response, defective resolution, and lack of response to receptor ligands ([@ref64]; [@ref146]; [@ref110]). Pivotal roles of ALX/FPR2 in regulating inflammation and resolution have also been unveiled in humans. Indeed, the amounts of ATL and ALX/FPR2 expression drive magnitude and duration of the acute inflammatory response in human volunteers undergoing experimental inflammation ([@ref133]). Hence, levels of ALX/FPR2 protein in tissues are fundamental to dictate the outcome of inflammation and its resolution. In this regard, [@ref198], [@ref199] and [@ref162] recognized molecular basis of ALX/FPR2 transcription, identifying the core promoter sequence, transcription factors, and epigenetic mechanisms (including microRNAs) able to control ALX/FPR2 expression, and an inheritable human SNP that weakens promoter.

![SPM GPCR and signaling pathways. To date, five specific SPM GPCRs have been identified in human and murine cells: ALX/FPR2, DRV1/GPR32, ERV1/ChemR23, DRV2/GPR18, and GPR37. Binding of SPM to their GPCR regulates cell-specific signaling pathways that ultimately diminish inflammation and enhance resolution. RvE1 also serves as a partial antagonist on leukotriene (LT) B~4~ BLT1 receptor to stop PMN infiltration.](fphar-10-00252-g004){#fig4}

Arita et al. reported that RvE1 bound with high affinity (*K*~d~ = 11.3 ± 5.4 nM) and stereoselectivity to cells overexpressing the GPCR ChemR23 (formerly known as chemerin receptor) ([@ref6]) and human PMN membranes (*K*~d~ \~50 nM). Interestingly, binding to PMN was displaced by homoligand RvE1 LTB~4~, and U-75302 (a selective LTB~4~ receptor 1 antagonist) ([@ref7]), indicating that RvE1 binding sites on human PMN are distinct from ChemR23. Lately, direct evidence for ligand-receptor interactions of RvE1 and its epimer 18S-RvE1 was reported using ChemR23 and BLT-1 β-arrestin cells with EC50 (\~6.3 pM) lower than that obtained with RvE1. In addition, the synthetic human chemerin-derived peptide (YHSFFFPGQFAFS), described as ligand for this same receptor ([@ref219]), displaced \[^3^H\]-RvE1 binding, indicating that RvE1 and chemerin share binding sites on ChemR23 ([@ref6]; [@ref92]). 18*S-*RvE1 also antagonized LTB~4~-mediated BLT1 activation in BLT-1 β-arrestin assays ([@ref501]). Hence, these results indicate that RvE1 and 18*S*-RvE1 share the same site(s) of binding to human ChemR23 and BLT-1.

RvE2 exerts potent and cell-specific actions on leukocytes ([@ref210]; [@ref151]) and binds to human PMN, ChemR23- and BLT-1 β-arrestin cells, with similar affinity to RvE1, indicating that these two SPMs partially share receptors ([@ref151]).

[@ref111] reported the identification of RvD1 receptors in human phagocytes. In their study, RvD1 reduced actin polymerization in human PMN in a pertussis toxin sensitive manner, did not activate Ca^2+^ release, nor induced cAMP formation in human PMN. In addition, \[^3^H\]-RvD1 selectively bound to human PMN and monocytes with high affinity (*K*~d~ \~0.17 nM) and was displaced LXA~4~ (\~60%), homoligand RvD1 (\~100%), but not an AnxA1-derived peptide ([@ref111]). Screening of a panel of GPCR established that RvD1 stopped NF-κB activation in cells overexpressing ALX/FPR2 or GPR32, but not other GPCRs (e.g., BLT1, BLT2, FPR, GPR-1, ChemR23, and CB1) treated with TNF-α. Moreover, RvD1 activated ALX/FPR2 and GPR32 in recombinant β-arrestin cells as did AT-RvD1, RvD1-carboxy-methyl ester, and a metabolically stable analog 17 (R/S)-methyl RvD1-ME ([@ref111]). Hence, renaming GPR32 as DRV1 receptor following the International Union of Basic and Clinical Pharmacology (IUPHAR) nomenclature has been proposed ([@ref4]).

Experiments using genetically modified mice, receptor antagonists, or blocking antibodies confirmed that ALX/FPR2 and GPR32 mediate the RvD1 immunoresolving actions ([@ref111]; [@ref78]; [@ref96]; [@ref171]; [@ref208]; [@ref14]; [@ref25]; [@ref118]; [@ref147]), that encompass modification of transcription factors, microRNAs, and genes ([@ref170]). Human GPR32 is mostly expressed not only on PMN, monocytes, and Mɸ, but also on vascular endothelial cells ([@ref111]). The murine ortholog of GPR32 is still unidentified, whereas it has been recently described in chimpanzees. Molecular circuits regulating GPR32 expression are unknown, while those of ALX/FPR2 have been reported and described ([@ref198]; [@ref162]; [@ref199]).

Specific receptors for RvD3 and RvD4 have not yet been recognized. However, RvD3 and AT-RvD3 both stimulate GPR32, which contributes to their pro-resolving activities (i.e., stimulation of Mɸ phagocytosis) ([@ref49]). Finally, Chiang et al. also demonstrated GPR32 activation by RvD5 ([@ref32]).

Earlier studies demonstrated that RvD2 biactions were inhibited by petussis toxin ([@ref200]), suggesting association with GPCRs. Chiang et al. identified the GPCR GPR18 as a RvD2 receptor in human leukocytes by using β-arrestin cell screening, binding of \[^3^H\]-RvD2 to recombinant GPR18, and genetic manipulation of this receptor ([@ref30], [@ref31]). Based on these findings, GPR18 has been renamed as DRV2 following the IUPHAR guidelines.

Tritium-labeled PD1 binding was demonstrated in retinal pigment cells (RPEs) and human PMN (Kd \~ 30 pmol/mg protein). Also, cold PD1 showed almost complete displacement of radio-labeled PD1, while other related omega-3 fatty acid compounds gave minimal or no displacement ([@ref126]). Recently, [@ref10] reported that PD1 binds with high affinity to HEK293 cells transfected with GPR37, a GPCR also known as parkin-associated endothelin-like receptor highly abundant in the brain. PD1 elicited Ca^2+^ increase in GPR37-expressing cells and peritoneal MΦs. The authors also found that GPR37 was required for conveying PD1 actions, like enhancement of phagocytosis. Hence, GPR37 is, *bona fide*, a PD1 receptor. Of interest, peptide (TX14) derived from prosaposin (a neurotrophic and myelinotrophic protein) shares binding to GPR37 and intracellular signaling with PD1, suggesting that this receptor, similarly to ALX and ChemR23, can mediate pro-resolution actions of both lipid and peptide ligands.

SPM interactions with their SPM regulate several intracellular mechanisms involved in inflammation. RvD1, RvD2, and RvE1 decrease NF-κB activation, nuclear translocation, and cytokine production ([@ref6]; [@ref66]; [@ref31]). RvE1 also signals the phosphorylation of the Akt-dependent ribosomal S6 kinase, which in turns stimulates MΦ phagocytosis ([@ref153]). Pioneer studies from [@ref171], demonstrated the role of microRNAs in mediating SPM actions in resolution circuits. In murine exudate leukocytes from zymosan-induced peritonitis, RvD1 regulates miR-21, miR-146b, miR-208a, and miR-219 in a time- and GPCR-dependent manner. Identified target genes of these microRNAs include IL-8, IL-10, and 5-LO that have pivotal roles in acute inflammation ([@ref171]; [@ref110]). In lung MΦ sorted from mouse lungs during *P. aeruginosa* chronic infection, RvD1 increased levels of miR-155 and miR-21 controls Toll-like receptor (TLR) expression and downstream proteins (e.g., MyD88), thus dampening signaling in MΦ that can fuel persistent inflammation ([@ref39]). In MΦ infected with *E. coli,* RvD1 dampens the expression of pro-inflammatory genes such as COX-2 ([@ref32]) and, along with LXA~4~ and 17*R-*RvD1, reduces cytokine production by MΦ induced by endotoxins ([@ref131]). Of interest, RvD2 also decreases the expression of TLR4, MyD88, and other accessory proteins in human monocytes, and these actions were partially due to the upregulation of miR-146a ([@ref43]). Therefore, regulations of MΦ responses *via* microRNAs, NF-κB, and TLR are a common mechanism of action of SPM.

SPMs are organ protective in experimental inflammation. LXA~4~ reduces kidney fibrosis and attenuates production of proteins stimulating fibrosis (e.g., fibronectin, N-cadherin, and thrombospondin) by upregulating microRNA let-7c and suppressing transforming growth factor (TGF)-β ([@ref19]). In human EC, LXA~4~ increases the release of extracellular vesicles enriched of miR-126-5p, which, upon uptake by neighbor cells, diminishes sprouty-related EVH1 domain containing one protein and enhances wound healing ([@ref40]). More recently, Mattè et al. found that oral administration of 17*R-*RvD1 in humanized sickle cell mice exposed to hypoxia/reoxygenation stress gave a marked increase in miR-126 and let-7 in lungs and kidneys, resulting in protection from inflammation-driven organ damage. Of interest, in the same model, 17*R-*RvD1 reduces activation of Nrf-2, a pivotal intracellular protein involved in chronic inflammation, and stimulates clearance of apoptotic PMN and damaged erythrocytes by MΦ ([@ref128]). Hence, SPMs act on multiple cellular pathways to stop further inflammation, protect from tissue damage, and stimulate pro-resolutive functions of MΦ.

Roles and Actions of SPM in CF {#sec15}
==============================

Several studies demonstrate that the ability of the CF lung to resolve inflammation is defective, thus contributing to the pathophysiology and progression of lung damage in patients. A study from Karp and colleagues found lower amounts of LXA~4~ in BAL of CF children as compared to non-CF pediatric patients with other respiratory infections ([@ref105]), and these findings were further corroborated by [@ref172]. Along these lines, Mattoscio and coworkers demonstrated that CFTR defects dampen LXA~4~ production during PLT:PMN interaction ([@ref129]). Based on these observations, acebilustat (CTX-4430), an oral inhibitor of LTA~4~ hydrolase, that prevents LTB~4~ biosynthesis has been tested in phase I and II clinical trials with volunteers with CF with the hypothesis that this compound could shut down LTB~4~ and turn on LXA~4~ biosynthesis. Adult with mild-to-moderate CF symptoms treated with acebilustat had a significant reduction in sputum PMN numbers and neutrophil elastase levels ([@ref68]). A larger phase II trial has been completed with the purpose of identifying the optimal patient population, dose, duration, and endpoints for future acebilustat trials and understanding the drug's efficacy in patients with CF ([@ref67]).

Observation of defective SPM biosynthesis and downstream pathways in patients with CF have provided the framework for testing new anti-inflammatory drugs that work by augmenting pro-resolving mediators. Lenabasum (JBT-101) is an oral agonist of cannabinoid CB2 receptor on leukocytes that trigger the biosynthesis of LXA~4~ that resolves experimental inflammation in mice ([@ref224]). A phase IIa clinical trial of lenabasum recently completed in CF ([@ref36]). At the end of the study, volunteers in the lenabasum arm showed a significant reduction in IL-8 and a trend downward reduced sputum neutrophil, elastase, and IgG compared to baseline. There was also a trend toward reduced risk of pulmonary exacerbations. Interestingly, recent results from Motwani et al. demonstrate that lenabasum carries potent anti-inflammatory and pro-resolving action in humans undergoing UV-killed *E. coli* skin injection ([@ref135]). In this study, lenabasum significantly reduced PMN numbers and pro-inflammatory prostanoids in exudates, whereas it increased levels of select SPM including RvD1 and LXA~4~. A multicenter phase IIb trial with volunteers 12 year of age or older in underway (NCT03451045).

Reduced 15-LO expression in nasal epithelial cells from CF patients has also been demonstrated ([@ref104]). The exact molecular link between CFTR dysfunction and altered LO expression and/or activity remains of interest. It has also been reported that patients with CF have an unbalance between AA and DHA levels in plasma and cells ([@ref112]; [@ref213]; [@ref79]; [@ref75]), which has prompted several studies aimed at restoring DHA levels with dietary supplementation of this omega-3 to patients ([@ref69]). Recently, works from [@ref161] demonstrate increased levels of the miR-181b in MΦ and epithelial cells from airways of CF individuals. Increased miR-181b leads to a reduction in ALX/FPR2 expression and blunts the ability of LXA~4~ and RvD1 to enhance bacterial clearance and epithelial integrity ([@ref161]). In another study, Bensalem and coworkers found that AnxA1 was diminished in intestine from CFTR^−/−^ mice and nasal epithelial cells isolated from volunteers with CF ([@ref16]). Also, inhibition of CFTR provokes an augmented inflammatory reaction in mice upon peritoneal injection of zymosan and delayed resolution related with reduced AnxA1 expression in peritoneal exudate leukocytes ([@ref51]). Thus, when resolution mechanisms are compromised, chronic inflammation will eventually ensue. Along these lines, restoration of AnxA1 levels with the recombinant protein corrected the overzealous inflammatory response seen with CFTR inhibition ([@ref51]).

Recent evidence signifies that SPMs convey protective biological activities to oppose excessive inflammation and tissue damage and to promote active return to homeostasis. During chronic *P. aeruginosa* infection in mice, RvD1 reduces PMN influx, dampens bacterial load, and ameliorates clinical sign of pathology. In addition, RvD1 also encourages *P. aeruginosa* clearance by human MΦ and PMN and *in vivo* shortened the time required to resolve inflammation. Of note, RvD1 showed comparable effects to ciprofloxacin treatment (the reference antibiotic lung exacerbation treatment in CF patients) in reducing both bacterial titer and leukocyte infiltration and demonstrated additional benefits to mono antibiotic therapy. Several cytokines and chemokines that are increased in CF airways were also diminished in mice bearing chronic *P. aeruginosa* infection by RvD1 treatment, including IL-8, IL-1β, and IL-17. RvD1 also exhibits pro-resolutive and protective actions in lung tissue since it strikingly lowers mucus metaplasia, parenchymal inflammation, and leukocyte infiltration in long-term infected *P. aeruginosa* mice ([@ref39]). Consistently, LXA~4~ stable analog reduces neutrophil recruitment and bacterial burden in short-term *P. aeruginosa* murine models of lung infection ([@ref105]). Along these lines, RvD2 reduces polymicrobial sepsis severity in mice ([@ref200]), RvD1 diminishes inflammation in pneumonia triggered by viral and bacterial co-infection ([@ref215]), whereas MaR1 and RvD3 enhance *E. coli* phagocytosis by MΦ ([@ref41]). Therefore, confining excessive inflammation and boosting host defense against pathogens are crucial SPM bioactions during resolution.

Many of actions exerted by SPM to limit inflammation and infection were also recapitulated with isolated human cells, such as the ability to enhance phagocytosis of bacteria by leukocytes ([@ref32]; [@ref42]; [@ref161]; [@ref39]). In addition, SPMs skew MΦ from a pro-inflammatory to a pro-resolutive phenotype ([@ref53]; [@ref170]; [@ref164]), for instance, enhancing the expression on MΦ of surface receptors involved in the uptake of apoptotic cells ([@ref128]).

SPMs target epithelial cells to regulate ion transport. LXA~4~ enhances CFTR-independent Cl^−^ efflux from CF bronchial epithelial cells and inhibits Na^+^ reabsorption, thus restoring the airway surface hydration (ASL) that is important for mucociliary clearance ([@ref214]; [@ref3]; [@ref98]; [@ref173]). RvD1 also enhances ASL height in human CF bronchial cells by reducing an amiloride-sensitive Na^+^ channel ([@ref173]). In airway epithelia exposed to bacterial infection *in vitro*, LXA~4~ and RvD1 proved to protect from cell injury, strengthen tight junction integrity, and reduce IL-8 production ([@ref87]; [@ref98]; [@ref173]).

SPMs counter inflammatory responses occurring in the vasculature. RvD1 reduces IL-1β-induced vascular permeability of EC and edema formation in lungs ([@ref39]) and limits PMN adhesion on EC and diapedesis ([@ref203]; [@ref146]), LXA~4~ and RvD2 stimulate NO production that stops leukocyte interactions with EC ([@ref156]; [@ref200]). LXA~4~ and B~4~ counter LTB~4~-induced PMN migration ([@ref155]), while RvE1 among SPM has the unique property of diminishing the number of PLT:leukocyte aggregates in human whole blood ([@ref62]) and ADP-induced PLT aggregation and activation ([@ref74]), which are enhanced in patients with CF.

Emerging evidence signifies now that SPMs are safe and effective in treating inflammatory diseases in humans. A small clinical trial with infants with eczema showed that topical application of a LXA~4~ stable analog was as potent as mometasone furoate in reducing disease severity, eczema area, and clinical scores, improving the quality of life of patients ([@ref220]). More recently, Kong and colleagues reported that LXA~4~ methyl ester was superior to corticosteroids in improving lung function of children with asthma and was well tolerated ([@ref107]). Finally, SPM proved to reduce neutrophil infiltration and bacterial endotoxins in volunteers subjected to UV-killed *E. coli* skin inflammation ([@ref136]).

Collectively, these data indicate that SPMs act at multiple levels on cells involved in the pathophysiology of CF airway inflammation and proved effective in preclinical models and clinical trials to stimulate resolution of chronic infection and inflammation, thus opening the road for SPM-based human resolution pharmacology.

Conclusion {#sec16}
==========

Anti-inflammatory drugs remain an area of intense research in CF, since it is unclear if and to what extent CFTR modulators will have a positive effect on the incipit and persistence of airway inflammation in patients. It is unlikely that these drugs will fully reverse the functional and structural damages present in patients with established disease or carry difficult to correct mutations. The development of drugs that stop excessive inflammation and promote resolution must proceed along with the identification of more suitable biochemical or cellular markers of effectiveness in patients. Furthermore, several aspects must be considered when evaluating new anti-inflammatories for CF: (1) mechanisms of actions and target cells/pathways, which should be broad and disease-related; (2) novelty of mode(s) of action with respect to traditional drugs used to limit inflammation (e.g., ibuprofen and steroids) that have provided little clinical benefits; (3) efficacy in appropriate preclinical models, including isolated cells, organs-on-a-chip derived, and biological samples (plasma, BAL) derived from patients, as well as animal systems; (4) toxicity; (5) *in vivo* impact on host defense mechanisms that are essential for containing infections; and (6) bioavailability and delivery methods that should take into account patients with lower compliance such as children.

Data from *in vitro* and *in vivo* studies indicate that SPMs are multi-pronged, potent regulators of inflammation and resolution, acting on multiple cell and molecular targets to limit the unwanted persistence of inflammation and tissue damage and accelerating the return to homeostasis ([Figure 5](#fig5){ref-type="fig"}). In addition, emerging results from clinical trials reporting safety and efficacy of SPM and molecules that stimulate their production encourage envisaging SPM as candidate drugs for treating chronic inflammation and infection in CF patients.

![Multipronged actions of SPM in CF airway disease. Broad actions of SPM relevant to CF airway disease encompass both anti-inflammation (limitation of further PMN infiltration, reduction in cytokine production, and decrease in lymphocyte, EC, and PLT activation) and pro-resolution (enhancement of MΦ phagocytosis and bacterial clearance, promotion of tissue repair, restoration of epithelial barrier integrity). See within text and references for further details.](fphar-10-00252-g005){#fig5}
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